Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03555825 · ClinicalTrials.gov registry record · Phase 3
Burke-Hocoma Efficiency Study
A Phase 3 study of Hemiparesis and Hemiplegia, sponsored by Burke Medical Research Institute.
- Completed
- Registry status
- Phase 3
- Development phase
- 47
- Enrollment target
- 1
- Study location
NCT03555825: Completed Phase 3 study of Hemiparesis and Hemiplegia, sponsored by Burke Medical Research Institute.
NCT03555825 is a Phase 3 study of Hemiparesis and Hemiplegia that has completed, run by Burke Medical Research Institute. The registered enrollment target is 47 participants, below the 58-participant average among 22 other Hemiparesis trials with a reported enrollment target (19% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03555825, a Phase 3 study of Hemiparesis and Hemiplegia, has completed, sponsored by Burke Medical Research Institute.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 47 participants
- Enrollment target
- 1
- Study location
Study Summary
The ArmeoSpring device is an exoskeleton (3 joints and 6 degrees of freedom) with integrated springs. The investigators hypothesize that 3 days of training for 6 weeks with the Hocoma Armeo Spring device will be efficient and more effective than one on one ArmeoSpring therapy.
Primary Outcome
Impairment measure of gross and fine motor upper extremity movements
Conditions Studied
Interventions
- DEVICE Hocoma ArmeoSpring
Study Locations (1)
New York
- Burke Medical Research Institute - White Plains
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2016-05-01 |
| Est. Completion | 2020-12 |
| Phase | Phase 3 |
What the finished NCT03555825 record still lists
NCT03555825 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 47 participants, a relatively small participant target, below the 58-participant average among 22 other Hemiparesis trials with a reported enrollment target (19% lower).
The record links to 2 conditions, with Hemiparesis appearing as the primary indexed condition, and to 1 intervention - of which Hocoma ArmeoSpring is the first listed.
NCT03555825 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT03555825 about?
NCT03555825 is a clinical study titled "Burke-Hocoma Efficiency Study". The ArmeoSpring device is an exoskeleton (3 joints and 6 degrees of freedom) with integrated springs. The investigators hypothesize that 3 days of training for 6 weeks with the Hocoma Armeo Spring device will be efficient and more effective than one on one ArmeoSpring therapy.
What is the current status of trial NCT03555825?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 47 participants. The study started on 2016-05-01. Estimated completion is 2020-12.
What conditions does trial NCT03555825 study?
This clinical trial studies the following conditions: Hemiparesis, Hemiplegia.
What interventions are being tested in trial NCT03555825?
The interventions under investigation include: Hocoma ArmeoSpring (DEVICE).
Who is sponsoring clinical trial NCT03555825?
This trial is sponsored by Burke Medical Research Institute, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03555825 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Hemiparesis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03555825's enrollment target sits among peer trials
47 10th of 22 higher than 13 of 22 other Hemiparesis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Hemiparesis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Mechanisms of Open and Hidden Placebo in Stroke Recovery
RECRUITING · NA
-
MyHand 2: An Active Hand Orthosis for Stroke Patients
RECRUITING · NA
-
Mapping Corticoreticulospinal Motor Control in Chronic Hemiparetic Stroke
RECRUITING · NA
-
Behavioral Assessment Method Index
RECRUITING
-
Human-Machine System for the H2 Lower Limb Exoskeleton
RECRUITING · NA
-
Assessment of a Physio-neuro Platform (SynPhNe) for Home-based Retraining of Hand Function in Stroke Survivors
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03313011 · 47 participants
The Neurobiology of Two Distinct Types of Progressive Apraxia of Speech
- NCT03467516 · 47 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal Melanoma
- NCT03886662 · 47 participants · Phase 1
A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)
- NCT04013802 · 47 participants · Phase 1
TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI